Search

Displaying results 8391 - 8400 of 10000 in total
  1. Drug

    Apoptone

    go.drugbank.com/drugs/DB06307
    Investigational

  2. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

  3. Drug

    Abafungin

    go.drugbank.com/drugs/DB06395
    Experimental

  4. Drug

    Dexanabinol

    go.drugbank.com/drugs/DB06444
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

  6. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.

  7. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    PW2101 is a beta blocker intended for the treatment of hypertension and angina. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  8. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI.

  9. Drug

    Velafermin

    go.drugbank.com/drugs/DB06493
    Investigational

    Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract. … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated

  10. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.